DAYBUE STIX Now Widely Available in the US for Rett Syndrome Treatment

Acadia Pharmaceuticals has announced that DAYBUE® STIX (trofinetide) is now widely available across the United States for the treatment of Rett syndrome. The company confirmed the expanded availability of this treatment option, which is specifically designed to address a rare neurological disorder that primarily affects females and leads to severe cognitive, motor, and communication impairments.

Rett syndrome impacts an estimated 6,000 to 9,000 individuals in the U.S., according to data cited by Acadia Pharmaceuticals. Trofinetide, marketed under the name DAYBUE® STIX, was developed as a targeted therapy aimed at addressing core symptoms associated with the condition. The product’s broader availability follows its initial approval by regulatory authorities and marks an effort to provide greater access for patients and healthcare providers managing this complex disorder.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 7, 2026

Author

GOAI